Biotech exposure from discovery to contract manufacturing, tiered by what stage the business is actually at.
Core — the theme IS a principal business todayGrowing — real operations, not yet the main businessAnnounced — committed plans or orders, little revenue yetMention-only — appears only as outlook language
Company describes an aspirational plan to build a CRDMO serving Biopharma (along with Pharma, medical devices, etc.) as part of an ongoing business transition; no specific biotech CRO/CDMO revenue or committed capex/JV is stated.
“In order to align our business with best global opportunities, we are working on a comprehensive plan to build a world class Contract Research, Development and Manufacturing Organization (CRDMO), which will eventually offer end-to-end research, development, manufacturing and allied services to our customers in Pharma, Biopharma, Agro-Chemicals, Medical Devices, Speciality Chemicals and similar industries”
How this list is built
Definition used: Discovers, develops or manufactures biologic drugs, vaccines, biosimilars, cell/gene therapies, or provides biotech CRO/CDMO services.Membership is extracted from each company’s newest annual report; every quote is validated against the report page before publishing, and core/growing tiers are confirmed by a second independent read (marked ). Companies whose reports our corpus hasn’t read yet simply aren’t listed — absence means unread, not “no exposure”.
MarketPing publishes facts, filings and measured history only — nothing on this page is investment advice, a recommendation or a rating.
